ACCP projects that it will have sufficient liquidity to fund operations at the current level (net cash burn rate for 1Q09 was $0.5M) through 1Q10 based on its current cash/equivalents ($2.2M at the end of 1Q09) and expected upfront, royalty, and milestone payments. At the end of 1Q09, ACCP we had convertible note outstanding in the principle amount of $5.5M that is due 9/13/11. During 2H09, Access plans to start multiple clinical trials for ProLindac and thiarabine, in addition to selling off its anti-infective dermatology assets (EcoNail, Pexiganan), which could provide additional upside catalysts for the stock price and cash to fund the continued development of the Company’s pipeline.
letzter Absatz
seekingalpha.com/article/...ng-to-advance-pipeline?source=feed